IBL-301 inhibited the PI3K-Akt and JAK/STAT pathways in vitro and in NSCLC tumor tissue explants and also inhibited secreted pro-inflammatory cytokine MCP-1 and warrants further preclinical and clinical investigation. Here, CCL2 is linked to neoplasm.